Stella-Jones (OTCMKTS:STLJF) Trading Down 2.9% – Time to Sell?

Stella-Jones Inc. (OTCMKTS:STLJF) shares fell 2.9% during mid-day trading on Monday . The stock traded as low as $56.24 and last traded at $56.3325. Approximately 14,264 shares traded hands during mid-day trading, an increase of 127% from the average daily volume of 6,291 shares. The stock had previously closed at $58.00.

Analyst Ratings Changes

Separately, Desjardins restated a “buy” rating on shares of Stella-Jones in a report on Thursday, May 7th. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy”.

Stella-Jones Stock Performance

The company has a market capitalization of $3.07 billion and a P/E ratio of 38.32. The company has a debt-to-equity ratio of 0.60, a current ratio of 4.96 and a quick ratio of 1.11. The stock’s 50 day simple moving average is $57.12 and its two-hundred day simple moving average is $63.12.

Stella-Jones (OTCMKTS:STLJF) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.82 EPS for the quarter, missing the consensus estimate of $0.84 by ($0.02). The company had revenue of $568.67 million for the quarter, compared to the consensus estimate of $583.30 million. Stella-Jones had a net margin of 8.66% and a return on equity of 14.92%.

Stella-Jones Company Profile

Stella-Jones Inc is a North American producer and distributor of pressure-treated wood products used in infrastructure, utility and residential applications. The company’s core offerings include treated railroad ties, utility poles, crossarms, landscape timbers and posts designed to withstand environmental stresses and extend service life. These products support a range of end markets from railways and power transmission to fencing and outdoor construction.

Founded in 1970 and headquartered in Montreal, Canada, Stella-Jones has grown through both organic expansion and targeted acquisitions to establish a network of manufacturing and treatment facilities across Canada and the United States.